Article info

Download PDFPDF
Extended Report
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial

Authors

  1. Correspondence to Dr Mette Bjørndal Axelsen, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Nordre Ringvej 57, opgang 5, stuen, Glostrup DK-2600, Denmark; mbaxelsen{at}gmail.com
View Full Text

Citation

Axelsen MB, Eshed I, Hørslev-Petersen K, et al
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial

Publication history

  • Received August 29, 2013
  • Revised November 30, 2013
  • Accepted December 15, 2013
  • First published January 10, 2014.
Online issue publication 
April 02, 2015

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.